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Long term comparison between captopril and nifedipine in the progres-
sion of renal insufficiency. To verify the hypothesis that angiotensin-
converting enzyme (ACE) inhibitors possess a unique renoprotective
effect in progressive chronic renal disease, we decided to compare the
effects of an ACE inhibitor and a calcium antagonist on both hyperten-
sion and the progression of non-diabetic renal insufficiency in a long-
term study, A four-year, multicenter, prospective, randomized trial was
conducted on 142 hypertensive patients (pts) with established chronic
renal failure from six Italian nephrology departments. They were on
standard antihypertensive therapy with a low-protein diet and under-
went twice-monthly surveillance for a one year pre-randomization
period. After that year, 121 pts were randomly allocated to captopril or
slow-release nifedipine therapies for a three-year study period. The
progression of renal insufficiency was monitored every two months.
Blood pressure control was significantly better after randomization than
during the year of standard antihypertensive therapy. The progression
rate before randomization (BR) was definitely higher before than after
randomization (AR): Creatinine clearance (Car) change BR = —0.46
0.45 mI/mm/month, creatinine clearance change AR = —0.23 0.43
ml/minlmonth (P < 0.01). After randomization, the mean blood pres-
sure values were virtually the same throughout the three year period of
the study in the two groups treated by captopnl (group I), or nifedipine
(group II). The progression rate of renal insufficiency evaluated by
1/serum creatinine (group I = —0.00326 0.0034dl/mg/month vs. group
II —0.00343 0.0039 dl/mg/month, P = NS), Ccr (group I = —0.22
0.38 vs. group II —0.24 0.4 mI/mm, P = NS), and the clearance of
9smTc DTPA (group 1 —0.20 0.38 mI/mm vs. group H = —0.22
0.4ml/min, P = NS) did not differ significantly between the two groups.
Moreover, the analysis of variance performed on the patients who
reached the end of the study did not show any differences between the
two groups either. During the three-year follow-up 14 patients on
nifedipine and seven patients on captopril therapy entered on chronic
dialysis treatment and were considered as end-points. The log-rank test
performed on the renal survival curves showed that the difference was
not significant (0.1 <P < 0.2). Thus, the better control of hypertension
achieved after randomization induced a slow-down in the progression
rate of renal insufficiency. The reduction in the progression rate induced
by the ACE inhibitor was no higher than that of the calcium antagonist
(CA). Our data are consistent with the hypothesis that both CAs and
ACE inhibitors possess a renoprotective effect.
A progressive deterioration in renal function inexorably
occurs in most forms of chronic renal insufficiency following a
critical reduction in functioning renal mass [1]. The mechanisms
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underlying the progression of renal disease are complex and
probably multifactorial [2]. Systemic arterial hypertension
(AH), which is a common complication of chronic renal failure,
is considered one of the most important risk factors in acceler-
ating the loss of function in the kidney with established paren-
chymal disease [3, 4]. On the basis of many experimental
studies, it has been suggested that AH may favor glomerulo-
sclerosis in association with compensatory glomerular hyper-
tension [1, 5] and/or structural glomerular hypertrophy [6], both
of which seem to mediate progressive glomerular injury. Since
angiotensin-converting enzyme (ACE) inhibitors are capable of
reducing both glomerular capillary hypertension and glomerular
hypertrophy [7, 8], it has been postulated that they may have
antihypertensive effects as well as a unique renoprotective
action on progressive glomerular injury [9]. Preliminary obser-
vations and retrospective studies seem to confirm that ACE
inhibitors are effective in delaying end-stage renal failure in all
forms of chronic renal failure [10—12]. However, there are no
prospective, randomized, long-term studies on humans analyz-
ing the clinical value of a reduction in blood pressure or the
beneficial effects of ACE inhibitors on the progression of
chronic renal failure. We report the results of a controlled
prospective, randomized multicenter trial on patients with
mild-to-moderate non-diabetic chronic renal insufficiency in
whom the long-term effects of an ACE inhibitor, captopril, were
compared to those of a calcium antagonist (CA), nifedipine.
Methods
Patient selection
A formal prospective, multicenter, randomized controlled
trial was planned in 1986. Eligible subjects were patients of both
sexes between 18 and 70 years of age with established chronic
renal failure, defined by a serum creatinine (S) concentration
ranging between 1.8 to 5.0 mgldl. Only women of non-child-
bearing potential were included. In the trial design, patients
were required to have: (a) a variation in plasma creatinine less
than 50% during the three-month preliminary observation pe-
riod; (b) a baseline diastolic blood pressure  95 mm Hg; (c) a
good general as well as nutritional condition.
Patients were excluded if they had potentially reversible renal
diseases, systemic diseases, severe cardiac or hepatic dysfunc-
tion, ankle edema or proteinuria greater than 5 g124 hr and
diabetes mellitus. Glomerulonephritis patients being treated
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with steroids, non-steroid anti-inflammatory agents and cyto-
toxic drugs were also excluded.
Study design
At the end of the three-month preliminary observation,
eligible patients in this outpatient study were encouraged to
follow or continue with a realistic low protein diet containing
0.6 to 0.7 g protein/kg body weight per day and a low sodium
diet with 60 to 100 smol/sodium per day. A caloric supply of 32
to 35 kcal/kg/24 hr was advised. Concomitant treatment con-
sisted of calcium carbonate during meals and allopurinol when
needed. No particular phosphate restriction was prescribed and
the use of vitamin D derivates was not allowed.
All the patients received traditional antihypertensive therapy
either with a single antihypertensive drug or with various
combinations of two or more agents. The most frequently used
medications were atenolol 50 to 100 mg/daily, pembutolol 40 to
80mg/daily, metoprolol 50 to 200 mg/daily, propanolol 60 to 160
mg/daily, furosemide 25 to 75 mg/daily, clonidine 0.150 to 0.450
mg/daily and hydralazine 50 to 75 mg/daily. Antihypertensive
drugs were left unchanged or adapted throughout the one-year
pre-randomization period in order to keep supine diastolic
blood pressure less than 95 mm Hg for as long as possible. ACE
inhibitors or calcium antagonists were not allowed during that
year. The same observer examined the patients at bi-monthly
intervals during the first year. Following the first-year control
period, the patients were randomly allocated to ACE inhibitor
(group I) or calcium antagonist (group II) treatment, After
randomization a three-year study period was planned for each
patient at bi-monthly intervals in their own nephrological out-
patient clinics. The initial captopril dose was 12.5 mg. b.i.d.
with a bia-weekly increase, either until blood pressure normal-
ization or until a maximum dosage of 50 mg. b.i.d. was reached.
The starting dose of nifedipine (slow release tablets) was 10 mg
b.i.d., after which the dosage was titrated every two weeks,
until blood pressure normalization was obtained or a maximum
dose of 20 mg b.i.d. was administered. Furosemide (25 to 75
mg/daily) and subsequently clonidine (0.150 mg b.i.d.) were
added if blood pressure had not been well controlled by
captopril or nifedipine alone. Twice-daily out-patient blood
pressure monitoring was advised for each patient in the two
groups. An identical diet was continued as for the first year, and
the clinical and laboratory check-ups were performed at the
same twice-monthly intervals.
Bi-monthly surveillance included a complete morning clinical
examination in which heart rate, systolic blood pressure and
diastolic blood pressure were measured immediately before
dose administration. Blood pressure was measured on the
patient's same arm four times after five minutes resting in
supine position (at consecutive 1-mm intervals) and once in
standing position. All blood pressure readings were performed
with a calibrated automatic recorder (Dynamap, Critikon,
Tampa, Florida, USA). The actual blood pressure value was
considered as the average of the four measurements. Mean
blood pressure (MBP) was calculated according to standard
formula. At each examination, body weight, ECG and routine
biochemical tests were performed, in particular, including se-
rum creatinine and urea, sodium and potassium both in plasma
and 24-hour urine, and 24-hour proteinuria. Creatinine clear-
ance (Cr) was then measured simultaneously during water
diuresis for three periods lasting 30 minutes each and averaged.
Clearances were normalized to a body surface area of 1.73 m2.
Chemical analyses of serum and urine were performed by
standard clinical laboratory techniques. Twenty-four hour pro-
teinuria was determined using a sensitive colorimetric method
(modification of the Coomassie Blue method) [13]. The interas-
say coefficient of variation for urinary protein concentration
was less than 5%. Serum and urine creatinine and urea nitrogen
concentration were measured with a Technicon AutoAnalyzer.
The reproducibility of the laboratory tests among the various
centers (creatinine, in particular) was assessed at the beginning
of the trial and after two years. The use of a common calibrant
was planned to avoid discrepancies in proteinuria between the
different centers. Compliance with diet was evaluated by twice-
monthly measurements of blood urea nitrogen and 24-hour
urinary nitrogen excretion. Protein intake was calculated from
24-hour urinary nitrogen according to Maroni, Steinman and
Mitch [14], and was confirmed by an experienced dietician.
Clearances of 99mTcDTPA were performed on the 48 pa-
tients followed up at two of the six nephrology centers that took
part in the study (Bologna and S. Giovanni Rotondo). These
measurements were taken at the beginning of the study and
every six months thereafter. Five mCi of the radioisotopic
marker were injected intravenously as single bolus during water
loading; clearances were calculated from the slope of the
plasma disappearance curve as previously reported [15].
The progression of renal insufficiency was evaluated for each
patient on the basis of the following criteria: (a) the reciprocal of
the serum creatinine concentration (l/S.) over time [16] and (b)
the regression line for C. (mean of the 3 measurements). The
rate of change in plasma clearance of 99mTcDTPA as a mea-
surement of GFR was also evaluated in the 48 patients enrolled
at Bologna and S. Giovanni Rotondo.
Lastly, the need for dialysis (Car below 4 mI/mm) was
considered as the end-point.
Statistical analysis
The results are expressed as means SD. The homogeneity
check of patient distribution between the two pharmacological
treatments was performed by means of the chi-square test for
non-parametric data, while it was done by means of the F-test
for parametric variables.
Regression lines for Car, the Cr and the 99mTcDTPA
clearance (when available) values over time were determined
for each patient who completed the study at least one year after
the randomization. The mean slopes were then calculated for
each treatment group. The resulting values were then used to
determine a mean value for the entire follow-up period. Stu-
dent's two-tailed t-test was used to compare the results of the
two groups.
The multivariate analysis of variance for repeated measure-
ments (MANOVA) was performed on the patients who reached
the end of the three-year study, to compare the effect of the two
drugs on the time course of blood pressure, renal function and
proteinuria. A multivariate test (Wilks test) and univariate tests
(F-tests) were also performed.
Lastly, actuarial renal survival was calculated for both treat-
ment groups and the log-rank test was used to assess the
difference in the survival curves.
454 Zucchelli et a!: Captopril and nifedipine in rena/failure
Table 1. Patient characteristics at randomization
Group I
captopril
Group II
nifedipine P
Number 60 61
Sex (M/F) 34/26 36/25 NS
Age years 55 10 55 10 NS
Body weight kg 70 11 69 13 NS
SBP mm Hg 166 19 164 22 NS
DBPmmHg 101± 14 99±11 NS
5Cr mg/dl 2.9 0.9 3.0 1.0 NS
Cr mI/mm 30 7 31 8 NS
Proteinunag/24hr 1.66 1.88 1.90 1.85 NS
Underlying renal disease
Glomerulonephritis 20 15 NS
Pyelonephritis or
interstitial nephritis 10 13 NS
Polycystic kidney disease 5 7 NS
Nephroangiosclerosis 18 18 NS
Unknown 7 8 NS
Control
period
G
c
1st
roup
aptop
2nd
I
ru
3rd
Group 11
nifedipine
1st 2nd 3rd
Patients who concluded, N 121 51 44 37 50 46 32
End-point need for dialysis 3 3 2 2 2 1 11
Non-renal death
Lack of cooperation 8 1 — 1 2 —
Drug intolerance 5 2 1 1 5 1 1
Concomitant disease 3 1 2 2 1 1 —
Other causes 2 2 1 1 1 1 1
Results
A total of 142 hypertensive patients (86 men) from six Italian
Nephrology Departments were enrolled on the trial, after giving
their informed consent. Their median age at entry was 56 years
(range 22 to 69). During the first-year control period with
standard antihypertensive treatment, 18 patients withdrew from
the study either owing to adverse drug effects (such as asthma,
severe bradycardia, orthostatic hypotension) or to an inability
to comply with appointments, medical schedules or diet; three
of the 18 patients who dropped out had concurrent illness or
surgery. A further three patients reached the end-point, that is,
a need for dialysis. Hence, 121 patients were randomly assigned
to group I or group II. Before randomization the patients were
not stratified according to the degree of renal impairment.
However, Sr and Cr were not statistically different between
the two groups at randomization (Table 1). Furthermore, the
l/Scr slope before randomization was not statistically different
between groups I and II (P = 0.710). Twenty-one patients in
group I and 24 patients in group II had a serum creatinine level
of 3.0 mgldl or over at the beginning of the study. The
characteristics of the two study groups at randomization are
shown in Table 1.
As can be seen in Table 2, 31 patients dropped out from the
trial during the three-year study period (16 patients from group
I and 15 from group II) due to concomitant diseases, non-renal
60
40
20
0
0 6 12 18 24 30 36
Time, months
Fig. 1. The renal non-survival curves of Group I (- - -, Captopril) and
Group II (—, Ntfedipine) patients studied for three years.
death, lack of cooperation and drug intolerance. The main
adverse effects were: Cough (2), taste disturbances (1) and
rhinitis (1) in group I; headache (3), severe ankle edema (3) and
severe flushing (1) in group II.
Twenty-one patients reached the end-point of the study (the
need for dialysis): Seven patients in group I (11.6%) and 14
patients in group 11(22.9%). The renal non-survival curves in
the two groups of patients were reported in Figure 1. A
statistically non-significant difference was found (0.1 <P < 0.2)
in spite of the higher number of end-points in group II when the
log-rank test between survival curves, in relation to the three
year period of the study, was performed. However, the differ-
ence became more pronounced in the last year when 11 patients
out of remaining 46 in the nifedipine group and only two
patients out of the 44 left in the captopril group reached
end-stage renal disease. The difference between the two groups
for this last year was highly significant (P < 0.005). The
end-point patients in both groups had a significantly higher Sr
than non-end-point patients at the beginning of the study, while
no difference was found in Sr at randomization between the
group I and group II patients who reached the end-point. There
was no difference between end-points and non-end-points as
regards proteinuria and MBP (Table 3).
Blood pressure control
Mean blood pressure was significantly higher during the first
year of standard antihypertensive therapy than during the three
years after randomization. On the other hand, when a compar-
ison was made between group I and group II no difference in the
average blood pressure levels was observed at any time during
the study (Fig. 2). In a very high percentage of patients, the
ACE inhibitor and the captopril treatments led to a stable
normalization of blood pressure. Furosemide was administered
in 40% of group I patients and in 41% of group II patients, while
20% of group I and 16% of group II patients required the
addition of clonidine. No patient required therapy to be discon-
tinued as a result of either symptomatic hypotension, acute
renal insufficiency or electrolyte abnormalities.
100
80>
Ci)
a)
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic
blood pressure; 5Cr' serum creatinine.
Table 2. Patient outcome during the trial at baseline, and after 1, 2
and 3 years of antihypertensive therapy
1 
a
 
I- 
I- I- 
—
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Table 3. Mean values at randomization in the end-pomt and non-end-point patients
Non-end
End points (21 pts)
Group I Group II
points captopril nifedipine
(100 pts) (7 pts) (14 pts)
NS
Sex (M/F) 59/41 — NS — 3/4
P < 0.0001
— NS — 8/6
Scr mg/d/ 2.7 0.7 P < 0.0001 — 3.8 1.03
NS
— NS — 3.9 0.78
Mean blood pressure (mm Hg) 117 11.6 — NS — 125 10.4
NS
— NS — 123 11.2
Proteinuria g/24hr 1.73 1.8 — NS — 1.58 1.8 —NS — 1.66 1.3
200
Table 4. Mean slope of reciprocal serum creatinine (i/Sc,) versus
time and mean rate of decline of creatinine clearance (Car) during
standard antihypertensive therapy and during captopril and nifedipine
therapies
Standard
antihypertensive Captopril Nifedipine
therapy therapy therapy
l/Scr dl/mg/month Mean
SD
— 0.0062
0.0038
0.00326a
0.00340
— 0.00343a
0.00390
Ccr mi/mm/month Mean
SD
— 0.46
0.45
0.22a
0.38
— 0.24's
0.40
a P < 0.01 vs. standard therapy.
Progression of renal insufficiency
The progression of renal insufficiency was examined in the
101 patients (51 on captopril and 50 on nifedipine) who com-
pleted at least one year after randomization. In the year of
standard antihypertensive therapy, the average slope in recip-
rocal serum creatinine plots was —0.0062 0.0038 dl/mg/month
and in the three years after randomization it was —0.0033
0.0039 dl/mg/month (P < 0.01). When we compared the capto-
pril group with the nifedipine group, the rate of change in renal
function did not differ significantly (Table 4). The mean decline
lfl Ci,. was 0.46 0.45 mL/min/month during the standard
antihypertensive therapy and 0.23 0.43 mllmin/month after
randomization (P < 0.001).
When the captopril and the nifedipine groups were separately
analyzed, the rate of change showed no statistical difference
(P = NS). Lastly, in the 48 patients whose GFR was evaluated
by 99mTcDTpA the rate of decline in GFR was 0.20 0.38
mi/mm/month in the captopril group and 0.22 0.40 ml/min/
month in the nifedipine group (P = NS). When the creatinine
clearances and the GFR values obtained by the radioisotopic
marker were correlated, we found a highly significant correla-
tion (r = 0.89, P < 0.001) between the two methods.
To examine the role of blood pressure control on the progres-
sion of renal insufficiency in more detail, we plotted the average
MBP obtained during the three-year treatment period with
lIScr. No statistical correlation was found between the two
variables (data not shown). Therefore, we subdivided the
patients according to the average of all the recordings of the
MBP levels during the three-year post-randomization follow-up
period. One group consisted of patients whose MBP levels
were constantly below or equal to 100 mm Hg, while the other
group consisted of patients with levels equal to or higher than
110 mm Hg, irrespective of the antihypertensive drug used.
Patients with unstable blood pressure values during the fol-
low-up were excluded. We observed that patients in the group
E
E
a)
ci)(I)
a)
0.
00
160
120
80
40
0
—12 —6 0 6 12 18 24 30 36
Time, months
Fig. 2. Average blood pressure levels in
chronic renal failure patients during the first
year of standard antihypertensive therapy and
during the 3 year period after randomization.
Symbols are: (El) standard antihypertensive
therapy; (LI) Group I (Captopril); () Group
II (Nifedipine).
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Table 5. Average values of mean blood pressure (MBP), creatinine
clearance (Car) and proteinuria in the 69 patients who underwent all
the scheduled controls during therapy with captopril (Group I) or
nifedipine (Group II)
Group
Time months
0 12 24 36
MBP
mmHg
CCr
mi/mm
Proteinuria
g/24 hours
I
II
I
ii
I
II
121 11
121 11
31±8
30 11
1.5 2
1.7 2
103 8
103 10
32±11
31 14
1.0 1.0
1.5 1.6
100 10
102 9
29±12
29 17
1.5 2.3
1.3 1.0
100 11
103 12
25±8
25 16
1.3 1.9
1.7 2.0
Data are means SD.
with MBP constantly below 100 mm Hg had a significantly
reduced level of proteinuria over time (on average 40% at the
end compared to the beginning of the study) and a slower
deterioration in renal function measured by l/Sr in comparison
to the other group of patients (—0.0027 0.0021 mg!dl/month
vs. —0.0053 0.0038 mg/dllmonth, respectively; P < 0.05).
Sixty-nine patients managed to conclude the three year
period. In these patients (32 in group I and 37 in group II) the
multivariate analysis of variance for repeated measures
(MANOVA) was performed to compare the effect of the two
drugs on the time course of MBP, 1/S, Car, and proteinuria.
The multivariate test showed no significant differences between
the nifedipine and captopril groups in the four variables taken as
a whole. Univariate tests were also performed to investigate the
effect of the two drugs on each variable. The tests showed no
significant differences for MBP (F-value 0.902, P 0.346) l/Sr
(F-value = 0.917, P = 0.342), proteinuria (F-value 0.11, P =
0.741) or for the CCr (F-value 0.03 1, P = 0.861), The behavior
of MBP, CC. and proteinuria in this group of patients is shown
in Table 5.
Moreover, in both groups we found no statistically significant
correlation between the slope in reciprocal serum creatinine
and the proteinuria trend during the three-year study period.
Dietary compliance was estimated by 24-hour urinary urea
excretion and dietary interview in each patient; the results were
then averaged for each group. In the control period (standard
therapy) the patients consumed a mean of 0.78 0.18 g of
protein per kilogram per day. The patients in group I (captopril)
had a mean of 0.76 0.15 g of protein per kilogram per day, as
compared with 0.77 0.19 g of protein per kilogram per day in
patients in group II (nifedipine), with no difference between the
groups. Moreover, body weight remained substantially un-
changed in all the patients.
Discussion
A one-year standard antihypertensive therapy and a low-
protein diet were planned before randomization so that only
patients who had already been controlled regularly at bi-
monthly intervals would be admitted to the study. Indeed, it has
been clearly documented [17] that frequent clinical examina-
tions have beneficial effects on the progression of renal failure.
Furthermore, the study of a population already being submitted
to a low-protein diet for some time prior to randomization
eliminates possible misinterpretations caused by sharp varia-
tions in protein intake. Indeed, many experimental and clinical
observations show that a protein restriction may slow down the
progression of chronic renal failure [18, 19].
Strong criticisms have been leveled against the use of the
reciprocal of serum creatinine and creatinine clearance to
follow the progression of chronic renal failure [20]. In fact, the
correlation of 1/Sr with true GFR must depend upon the
consistency of the urinary creatinine excretion rate, whereas it
is now recognized that urinary creatinine can be modified by
changes in dietary protein [20]. The use of Cr should avoid this
problem, and indeed, several authors have recently supported
its clinical value in measuring GFR during water diuresis [21].
However, tubular secretion of creatinine may to some extent
also be affected by dietary intake [21]. Hence, both 1/Sr and
Ccr may be inaccurate in measuring the progression rate of
renal insufficiency when significant changes in protein intake
occur. In our patients such problems were overcome by the
constant protein intake maintained throughout the study. More-
over, renal function was also monitored in approximately 40%
of our patients by means of 99mTc..DTpA clearance, whose
utility in measuring GFR accurately has been confirmed in
subjects with renal insufficiency [22].
At first our study underlined the importance of the control of
systemic hypertension per Se in patients with chronic renal
failure. Better blood pressure control was associated to a lower
rate of decline in renal function during the three-year study
period with ACE inhibitor and calcium antagonist treatment.
Although systemic hypertension has been considered to be a
major risk factor for progressive renal disease, careful docu-
mentation of its deleterious effects has only been derived from
experimental models [3, 4]. Moreover, evidence that antihyper-
tensive therapy retards the progression of chronic renal failure
in humans is limited to retrospective studies [231 or to a small
number of patients followed up for a limited period of time [10,
12]. In our large population of prospectively studied patients,
antihypertensive treatment with an ACE inhibitor and a calcium
antagonist (CA) produced a significantly better control of blood
pressure than with standard antihypertensive therapy. This was
not altogether unexpected since ACE inhibitors and CAs have
both been shown to be effective antihypertensive drugs which
can improve hypertensive patients' quality of life, mitigating the
side-effects common to other antihypertensive agents [24, 25].
Indeed, our patients achieved better compliance to the therapy
after randomization. Better blood pressure control was associ-
ated to a lower rate of decline in renal function during the
three-year study period with ACE inhibitor and calcium antag-
onist treatment. Indeed, after randomization, the subgroup of
patients whose mean blood pressure level was equal to or below
100 mm Hg showed a net decrease in proteinuria and in the
progression rate compared to the subgroup of patients whose
MBP levels were higher than 110 mm Hg. These data further
confirm the role of aggressive blood pressure control per se in
renal damage and stress the need for a target blood pressure
level which is significantly below what is routinely considered
to be acceptable.
It has been postulated on the basis of animal experiments that
ACE inhibitors have a unique renoprotective action on progres-
sive glomerular injury [7, 81. In fact, the prevention of adaptive
glomerular capillary hypertension and/or the mitigation of adap-
tive morphological changes with ACE inhibitors in various
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experimental models does actually protect against the subse-
quent development of structural injury within the remaining
glomeruli. Although it is not thoroughly understood how rele-
vant such animal studies are in humans with renal disease, some
retrospective studies [8] or prospective short-term trials on
small patient samples [11, 12] appear to confirm that the control
of systemic hypertension by ACE inhibitors may be effective in
slowing down the progression rate of renal failure.
In addition, these drugs may have an antiproteinuric action
[261. Hence, we decided to study the long-term effects of ACE
inhibitor administration on hypertensive patients with non-
diabetic chronic renal failure. We chose not to compare capto-
pril with a placebo because we thought this comparison would
have been unethical, considering the length of our study and the
likely consequent systemic cardiovascular risk for the untreated
patients. We decided to compare captopril with the CA, namely
nifedipine, because CAs, being both effective and safe antihy-
pertensive agents, are widely used in patients with chronic renal
failure [25]. Another reason why CAs were selected for com-
parison with ACE inhibitors was that many of their effects on
renal hemodynamics seem to be quite unlike those of the latter
drugs. In fact, CAs decrease the ability of the kidney to
autoregulate the renal blood flow and the glomerular filtration
rate, and they decrease afferent renovascular resistance [27]. In
contrast, ACE inhibitor administration results in efferent vaso-
dilation while the afferent vasculature is practically unaffected
[8, 27]. Hence, from a theoretical point of view, CAs do not
seem particularly apt to preventing the glomerular hemody-
namic changes that are judged to be involved in the progression
of renal disease. Some experimental studies [28, 29], though not
all [30, 31], confirm the above theoretical consideration because
CAs seem to adequately control blood pressure without affect-
ing progressive renal disease.
In our multicenter prospective study, the administration of an
ACE inhibitor over a three-year period did not confer superior
protection against progressive renal damage in comparison to a
CA. In fact, when captopril was compared to nifedipine, the
former did not seem to significantly better stabilize renal
function, while the rate of progression was practically the same
in the two treatment groups.
How can we reconcile our results with the experimental data
and the preliminary observations in humans?
First of all, in many of the previous studies [11, 12] ACE
inhibitors were compared with drugs other than CAs. Hence, it
is quite plausible that both ACE inhibitors and CAs have an
intrinsic renoprotective action. Recent experimental studies
have suggested the CAs are as effective as ACE inhibitors in
preventing progressive renal damage [31] and in mitigating renal
diseases characterized by mesangial cell proliferation [32].
Moreover, the relatively low rate of progression found in our
patients, in comparison to the period of standard antihyperten-
sive therapy and compared to the mean progression rate that
had previously been reported by various authors [23, 33], may
further uphold this hypothesis.
Secondly, an interaction between dietary protein intake and
the renin-angiotensin system has been reported. In fact, plasma
renin activity varied according to the level of dietary protein,
being higher on a high protein diet [34]. Indeed, it has been
demonstrated that the effect of ACE inhibitors on glomerular
permselectivity depends on the previous dietary protein intake
[35]. Thus it can be argued that the lack of any difference found
in our patients between captopril and nifedipine may be partly
due to their moderately low protein intake.
Thirdly, ACE inhibitors might prevent the progression of
renal damage only when renal function is slightly reduced,
without having any effects on more advanced renal failure [36].
In a rat remnant kidney model, in fact, ACE inhibition effec-
tively preserved the structure of glomeruli with early or no
sclerotic lesion, whereas it exerted little effect on glomeruli with
advanced sclerotic lesions.
Finally, the higher number of end-points in the nifedipine
group, compared to the number in the captopril group, although
not statistically significant, warrants further consideration. The
slightly higher number of patients having Sr of 3.0 mg/dl or
over at the beginning of the study in the group 11(24 vs. 21)
could partly account for the difference in the number of
end-points between the two groups. Furthermore, it cannot be
excluded that a larger or longer trial would have demonstrated
a more favorable effect of ACE inhibitors (type II error).
We can therefore conclude that both CAs and ACE inhibitors
have been able to slow down the progression rate of our
hypertensive patients. It is at present unknown whether this
protection is solely due to better blood pressure control or to
other non-hemodynamic factors, such as the absence of dele-
terious metabolic effects [37], or to the attenuation of mesangial
cell proliferation and mesangial expansion [9], or to some sort
of protection against progressive atherosclerosis [38, 39].
In conclusion, our multicenter trial stresses the importance of
good pressure control in the protection of human kidney
damage. Our data do not definitively support the belief that
ACE inhibitors have a unique renoprotective effect, indepen-
dent of blood pressure control, because CAs that induce an
equal blood pressure reduction slow down the progression of
renal insufficiency to the same extent as the ACE inhibitors.
However, it is worthwhile noting that our data were obtained
from protein-restricted subjects and may not be applicable to
subjects on a free protein intake. Moreover, our patients were
at a relatively advanced stage of renal failure, thus the superi-
ority of ACE inhibitors over CAs at an early stage of renal
damage cannot be excluded. Lastly, our data are consistent
with the hypothesis that in renal insufficiency ACE inhibitors
and CAs both possess an intrinsic renoprotective effect, not
necessarily exerted in the same way.
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